India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
ALS patients experience neuroinflammation and rapid neurodegeneration
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
The recent inspection covered both cGMP and PAI processes
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Effective, holistic, science-backed targeted solutions for symptomatic treatment
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Subscribe To Our Newsletter & Stay Updated
